Novo Nordisk partners with OpenAI

Pharmaceutical giant Novo Nordisk has entered into a strategic partnership with artificial intelligence leader OpenAI. This collaboration is designed to accelerate the discovery and development of novel therapeutic treatments, potentially leading to faster market entry for new medicines. By leveraging OpenAI's advanced AI capabilities, Novo Nordisk aims to enhance its research pipeline and identify groundbreaking therapies, similar to the success seen with its blockbuster drug Ozempic.